A day after the US Food and Drug Administration (FDA) granted emergency approval as booster shots for two vaccines tailored to the ommicron variants of the coronavirus circulating, the European Medicines Agency (EMA) followed suit on Thursday and gave the green light for adoption of two ommicron boosters.
In an extraordinary meeting, the responsible EMA committee voted in favor of the approval of the omicron vaccine from Biontech/Pfizer and Moderna. According to the EMA, approval was recommended for people 12 years and older who are at least basic immunized against SARS-CoV-2. The European Commission must now make a formal decision on the approval of the vaccines. She is expected to do this in a timely manner.
The meeting of the Committee for Medicinal Products for Human Use (CHMP) discussed Biontech/Pfizer and Moderna’s applications for vaccines to protect against the parental coronavirus and its omicron variant BA.1. It is hoped that these vaccines will also work against the currently circulating BA.4 and BA.5 subtypes.
As early as mid-August, the British Medicines Agency gave the green light for Moderna’s bivalent vaccine, which, like the Biontech vaccine, is effective against both the original coronavirus strain and the omicron subvariant BA.1.
Completely clear for continuation of the vaccination campaign
The decision of the EMA and the European Commission clears the way for the continuation of the vaccination campaigns. Only on Wednesday did the National Vaccination Commission (NIG) recommend the corona booster vaccination for everyone above the age of twelve. Until now, the recommendation for the fourth stitch has been for people over the age of 60.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
